Breast Cancer (BC) is one of the most common types of malignancies in women worldwide. Breast tumorigenesis is
unrecognized because of a diversity of risk factors in context to bio-molecular dynamics. This present study was to inhibit the
expression of the DMNT1 by a secondary metabolite with the help of molecular docking for the treatment of Breast Cancer. The
rational drug design together with structure-based modeling and rapid screening tools or potential for the reason that
characteristic and developing lead malignant tumor molecules. Thus, the molecular docking method plays an important role in
screening a large set of molecules based on their free binding energies and proposes structural hypotheses of how the molecules
can inhibit the target
